Profile data is unavailable for this security.
About the company
Paradigm Biopharmaceuticals Limited is a late-stage drug development company. It is engaged in researching and developing therapeutic products for human use. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS clears cellular and tissue accumulation of GAGs. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses (MPS); treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).
- Revenue in AUD (TTM)8.67m
- Net income in AUD-69.00m
- Incorporated2014
- Employees--
- LocationParadigm Biopharmaceuticals LtdLevel 15, 500 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39629-5566
- Fax+61 39629-5466
- Websitehttps://paradigmbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inoviq Ltd | 751.54k | -6.51m | 44.63m | 85.00 | -- | 2.67 | -- | 59.38 | -0.0708 | -0.0708 | 0.0082 | 0.182 | 0.0339 | 2.10 | 0.873 | -- | -29.33 | -47.68 | -32.18 | -50.76 | 95.07 | -- | -866.27 | -2,527.82 | 4.93 | -- | 0.0332 | -- | 119.59 | 153.31 | 50.71 | -- | -- | -- |
| Starpharma Holdings Ltd | 10.63m | -8.40m | 49.44m | 50.00 | -- | 1.43 | -- | 4.65 | -0.0205 | -0.0205 | 0.0259 | 0.0837 | 0.2092 | 0.282 | 2.10 | -- | -16.53 | -28.47 | -20.70 | -33.66 | 92.67 | 71.62 | -79.00 | -391.82 | 5.22 | -- | 0.0833 | -- | -14.10 | -3.22 | 3.19 | -- | 11.58 | -- |
| Anteotech Ltd | 526.75k | -11.46m | 50.58m | 40.00 | -- | 9.71 | -- | 96.02 | -0.0056 | -0.0056 | 0.0003 | 0.0022 | 0.0552 | -- | 2.62 | -- | -120.11 | -68.55 | -145.22 | -75.44 | -- | -- | -2,176.15 | -1,432.10 | -- | -- | 0.1729 | -- | -46.65 | 11.41 | -18.08 | -- | 25.84 | -- |
| Biotron Ltd | 1.65m | -4.02m | 54.14m | 4.00 | -- | 28.96 | -- | 32.91 | -0.0045 | -0.0045 | 0.0018 | 0.0021 | 0.3587 | -- | -- | -- | -87.73 | -64.30 | -103.46 | -74.43 | -156.30 | -108.03 | -244.54 | -231.62 | -- | -- | 0.0148 | -- | -8.16 | -2.48 | -25.59 | -- | -- | -- |
| Vitura Health Ltd | 119.67m | 9.40m | 63.35m | 121.00 | 6.68 | 1.61 | 16.75 | 0.5293 | 0.0165 | 0.0165 | 0.2099 | 0.0681 | 1.98 | 11.22 | 10.51 | 989,034.20 | 15.25 | 15.29 | 22.30 | 21.06 | 31.23 | -- | 7.70 | 6.92 | 1.18 | 5,598.19 | 0.2359 | -- | 75.16 | -- | 128.31 | 146.95 | 54.86 | -- |
| Percheron Therapeutics Ltd | 624.51k | -10.85m | 69.42m | 8.00 | -- | 4.22 | -- | 111.16 | -0.0157 | -0.0157 | 0.0009 | 0.0182 | 0.0328 | -- | 0.3224 | -- | -56.94 | -72.09 | -66.58 | -81.73 | -- | -- | -1,737.37 | -6,558.90 | -- | -- | 0.001 | -- | 1,026.16 | 72.03 | -95.81 | -- | -- | -- |
| Biome Australia Ltd | 10.24m | -2.86m | 70.23m | 30.00 | -- | 32.58 | -- | 6.86 | -0.0141 | -0.0141 | 0.0506 | 0.0101 | 1.37 | 1.93 | 6.04 | 341,434.70 | -38.27 | -- | -74.60 | -- | 61.29 | -- | -27.97 | -- | 0.9514 | -15.92 | 0.4032 | -- | 73.58 | -- | 32.20 | -- | -- | -- |
| Actinogen Medical Ltd | 337.51k | -14.87m | 74.46m | -- | -- | 6.16 | -- | 220.62 | -0.0074 | -0.0074 | 0.0002 | 0.0052 | 0.0211 | -- | 0.7341 | -- | -92.99 | -45.55 | -105.88 | -48.24 | -- | -- | -4,405.86 | -5,369.76 | -- | -294.93 | 0.0037 | -- | 792.74 | 31.88 | -13.21 | -- | 166.95 | -- |
| Argenica Therapeutics Ltd | 92.21k | -4.67m | 76.15m | -- | -- | 9.32 | -- | 825.80 | -0.0511 | -0.0511 | 0.001 | 0.0665 | 0.0109 | -- | 0.6384 | -- | -55.31 | -- | -69.00 | -- | -- | -- | -5,067.62 | -- | -- | -6,663.20 | 0.00 | -- | 2,340.00 | -- | -17.71 | -- | -- | -- |
| Orthocell Ltd | 6.06m | -7.42m | 78.50m | -- | -- | 34.31 | -- | 12.96 | -0.0369 | -0.0369 | 0.0301 | 0.0109 | 0.2182 | 1.50 | 27.68 | -- | -26.73 | -32.67 | -31.96 | -38.53 | 77.11 | 63.04 | -122.55 | -374.46 | 4.36 | -- | 0.2586 | -- | 215.24 | 51.53 | 31.39 | -- | 11.07 | -- |
| PharmAust Limited | 1.85m | -7.79m | 86.90m | 52.00 | -- | 11.03 | -- | 46.95 | -0.0236 | -0.0201 | 0.0055 | 0.02 | 0.1977 | -- | 6.71 | -- | -83.26 | -25.56 | -96.46 | -28.78 | 20.06 | 90.73 | -421.04 | -59.16 | -- | -104.65 | 0.00 | -- | -13.53 | 3.42 | -263.63 | -- | -47.47 | -- |
| Paradigm Biopharmaceuticals Ltd | 8.67m | -69.00m | 89.20m | -- | -- | 2.65 | -- | 10.29 | -0.2296 | -0.2296 | 0.0288 | 0.0962 | 0.1298 | -- | 2.25 | -- | -103.34 | -40.96 | -127.58 | -44.13 | 99.87 | -- | -796.30 | -466.85 | -- | -348.76 | 0.0085 | -- | 7.58 | 25.42 | -32.26 | -- | -- | -- |
| Next Science Ltd | 33.48m | -24.56m | 105.01m | -- | -- | 5.43 | -- | 3.14 | -0.1062 | -0.1062 | 0.143 | 0.0664 | 1.46 | 7.47 | 8.33 | -- | -107.19 | -74.40 | -136.06 | -90.31 | 73.20 | 76.98 | -73.36 | -128.26 | 3.45 | -50.37 | 0.0698 | -- | 89.36 | 50.80 | -28.29 | -- | -2.28 | -- |
| Vita Life Sciences Limited | 74.16m | 9.08m | 123.75m | 124.00 | 13.37 | 2.89 | 12.90 | 1.67 | 0.166 | 0.166 | 1.36 | 0.7695 | 1.33 | 2.34 | 7.35 | -- | 16.27 | 15.25 | 22.51 | 21.99 | 58.14 | 60.90 | 12.24 | 11.71 | 2.29 | -- | 0.0089 | 39.05 | 10.88 | 12.50 | 28.18 | 30.07 | 12.15 | 19.14 |
| Arovella Therapeutics Ltd | 139.02k | -10.23m | 131.27m | 14.00 | -- | 36.29 | -- | 944.25 | -0.0127 | -0.0127 | 0.0002 | 0.0034 | 0.0249 | -- | 15.15 | -- | -182.82 | -77.12 | -276.07 | -93.26 | 83.56 | 63.41 | -7,357.19 | -1,471.57 | -- | -- | 0.00 | -- | 45.47 | 0.3491 | -18.11 | -- | -68.72 | -- |
Data as of May 08 2024. Currency figures normalised to Paradigm Biopharmaceuticals Ltd's reporting currency: Australian Dollar AUD
14.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Allianz Global Investors Asia Pacific Ltd.as of 31 Dec 2023 | 13.77m | 4.44% |
| RBC Global Asset Management (Asia) Ltd.as of 29 Feb 2024 | 9.69m | 3.13% |
| Netwealth Investments Ltd.as of 14 Aug 2023 | 7.40m | 2.39% |
| Allianz Global Investors Singapore Ltd.as of 31 Dec 2023 | 3.60m | 1.16% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.33m | 0.75% |
| Pictet Asset Management SAas of 31 Dec 2023 | 2.25m | 0.73% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.17m | 0.70% |
| Perennial Value Management Ltd.as of 14 Aug 2023 | 1.65m | 0.53% |
| Pictet Asset Management (Singapore) Pte Ltd.as of 31 Dec 2023 | 906.94k | 0.29% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 275.49k | 0.09% |
More ▼
Data from 31 Jul 2021 - 01 May 2024Source: FactSet Research Systems Inc.
